Opus Genetics receives Sandoz Paragraph IV notice challenging six RYZUMVI patents

Opus Genetics, Inc.

Sandoz filed ANDA for generic RYZUMVI; alleges six Orange Book patents invalid/unenforceable/non-infringed.
Challenged patents: 9,795,560, 10,278,918, 10,772,829, 11,090,261, 11,844,858, and 11,400,077.
Two other RYZUMVI Orange Book patents (12,201,615 and 12,201,616) not challenged by Sandoz.
Opus or its commercial partner may file patent infringement lawsuit to defend IP rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.